PT  - JOURNAL ARTICLE
AU  - Alexander, Lori
ED  - Borer, Jeffrey S.
TI  - Ivabradine Effect on Recurrent Hospitalization for HF
DP  - 2012 Nov 01
TA  - MD Conference Express
PG  - 25--26
VI  - 12
IP  - 13
4099  - http://mdc.sagepub.com/content/12/13/25.short
4100  - http://mdc.sagepub.com/content/12/13/25.full
AB  - The Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial [SHIFT] was a randomized, double-blind, placebo-controlled trial in 6505 patients with moderate to severe chronic heart failure (HF), which tested whether isolated heart rate reduction with the If inhibitor ivabradine improves cardiovascular outcomes [Swedberg K et al. Lancet 2010]. Since a significant proportion of healthcare resource and economic burden is attributable to recurrent hospitalization in patients with HF, the aim of the current analysis was to assess the effect of treatment with ivabradine on recurrent hospitalizations for worsening HF throughout the entire duration of SHIFT [Borer JS et al. Eur Heart J 2012].